What are Eli Lilly's updated full-year 2026 revenue and adjusted earnings per share forecasts, and how do they compare to previous guidance?

Eli Lilly now expects 2026 full-year revenue of $85 billion to $87 billion, up from its prior forecast of $82 billion to $85 billion. For adjusted earnings per share, it revised the range to $35.50 to $36.50, trimming the top end from its earlier $35.50 to $37.00 guidance, citing charges related to business activity in the quarter.

How did Mounjaro and Zepbound perform in the latest quarter, and what share of Lilly's total revenue did they collectively account for?

In the latest quarter, Mounjaro sales rose 91% to $9.94 billion and Zepbound sales reached $4.93 billion — both exceeding analyst expectations — and together they accounted for 64.7% of Lilly's total revenue.

Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Aug 5, 2026

Eli Lilly raised its full-year revenue forecast following better-than-expected quarterly results driven by GLP-1 drug sales Mounjaro and Zepbound. Shares surged 5% amid resilient demand despite pricing pressures and competition from Novo Nordisk.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks